Lilly Responds to Growing Patient Reports of GI Discomfort
Two weeks after the blockbuster launch of Foundayo, Eli Lilly's next-generation GLP-1 receptor agonist, the company has issued updated prescribing guidance addressing a wave of patient-reported nausea and gastrointestinal side effects. The guidance, distributed to healthcare providers on Sunday, outlines specific titration adjustments and dietary recommendations aimed at reducing discomfort during the initial dosing period.
Foundayo, which received FDA approval on March 14 and became available in pharmacies on March 24, has already been prescribed to an estimated 1.2 million patients in the United States, according to IQVIA prescription tracking data. The drug represents Lilly's most significant product launch since tirzepatide.
What Patients Are Experiencing
Reports aggregated from patient forums, pharmacy feedback channels, and healthcare provider surveys indicate that approximately 18% of patients are experiencing mild to moderate nausea during the first 10 to 14 days of treatment. An additional 7% have reported other gastrointestinal symptoms including bloating, constipation, and acid reflux.
"The side effect profile we are seeing in real-world use is consistent with what our Phase III clinical trials demonstrated. These are largely transient effects that resolve as the body adjusts to the medication," said Dr. Daniel Skovronsky, Lilly's Chief Scientific Officer, in a statement.
In the pivotal FOUNDRY-3 trial, 19.2% of participants in the treatment arm reported nausea during the first four weeks, compared to 4.1% in the placebo group. By week eight, the rate had dropped to 6.8%. Lilly emphasized that fewer than 3% of trial participants discontinued treatment due to gastrointestinal side effects.
Updated Dosing Guidance
The new guidance recommends several modifications for patients experiencing GI discomfort:
- Extended titration period: Patients may remain on the 2.5 mg starting dose for four weeks instead of two before escalating to 5 mg
- Meal timing: Taking Foundayo within 30 minutes of a protein-rich meal rather than on an empty stomach
- Hydration protocol: Consuming at least 64 ounces of water daily, with emphasis on small, frequent sips rather than large volumes
- Temporary dietary adjustments: Avoiding high-fat and heavily spiced foods during the first three weeks of treatment
Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, noted that the updated guidance reflects standard practice for the GLP-1 drug class.
Social Media Amplification
The side effect reports have gained significant traction on social media platforms. The hashtag #FoundayoNausea has accumulated over 9 million views on TikTok since Thursday, with users sharing personal experiences ranging from mild queasiness to episodes requiring missed work days. Several posts have gone viral, amplifying concerns beyond what clinicians consider typical for this medication class.
Lilly's communications team has responded by launching an informational campaign through its FoundayoSupport.com portal, which now features a dedicated FAQ section on managing early side effects and a direct line to a nurse-staffed support center operating seven days a week.
"We want every patient to have realistic expectations about the adjustment period. Most people find that side effects diminish significantly after the first two to three weeks," said Dr. Skovronsky.
Pharmacy and Provider Perspectives
Pharmacists report that the most common questions from Foundayo patients center on whether the nausea indicates the medication is not right for them. Mark Gonzalez, a clinical pharmacist at CVS Health, said his team has been proactively counseling patients at the point of dispensing about potential GI effects and when to contact their prescribers.
Endocrinologists and obesity medicine specialists have largely characterized the side effects as manageable and expected. Dr. Fatima Cody Stanford of Massachusetts General Hospital emphasized that patients should not discontinue Foundayo without consulting their provider, as abrupt cessation can lead to rapid weight regain.
Market Impact and Supply Update
Despite the headlines, Lilly's stock has shown resilience. Shares closed Friday at $892.14, down only 1.3% for the week. Analysts at Morgan Stanley maintained their overweight rating, noting that the side effect profile is well within the range observed across the GLP-1 drug class and is unlikely to materially impact adoption rates.
On the supply front, Lilly confirmed that Foundayo remains available at approximately 87% of retail pharmacies nationwide, with the 2.5 mg and 5 mg starter doses showing the tightest inventory. The company expects to reach full supply equilibrium by late April.
